Q3 2025 InspireMD Inc Earnings Call Transcript
Key Points
- InspireMD Inc (NSPR) reported a 39% year-over-year revenue growth, reaching $2.5 million in the third quarter of 2025.
- The company successfully launched CGuard Prime in the US, contributing significantly to revenue growth.
- InspireMD Inc (NSPR) has completed over 100 cases in the US, indicating strong initial demand for CGuard Prime.
- The company has a robust pipeline with ongoing clinical trials, including C-GUARDIANS II and III, which could unlock additional market opportunities.
- InspireMD Inc (NSPR) raised significant capital through a PIPE offering and milestone-based financing, increasing cash resources to $63.4 million.
- The company reported a net loss of $12.7 million for the third quarter of 2025, an increase from the $7.9 million loss in the same period of 2024.
- Operating expenses increased by 57% to $13.9 million, driven by higher headcount-related expenses and infrastructure costs.
- Financial income decreased by $229,000 due to lower returns from investments and increased financial expenses related to exchange rates.
- The gross margin, although improved, is still relatively low at 34.2%, indicating room for further improvement.
- The company faces challenges in scaling its sales force and ensuring consistent product adoption across new accounts.
Good morning, and welcome to InspireMD third-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Webb Campbell from Gilmartin Group for introductory disclosures. Please go ahead.
Thank you for joining us for the InspireMD Third Quarter 2025 Conference Call. Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer; Mike Lawless, Chief Financial Officer; and Shane Gleason, Chief Commercial Officer.
During this call, management will make forward-looking statements, which are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed in such forward-looking statements. For more information about these risks, please refer to the risk factors described in InspireMD's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
